文献速递银屑病与炎症性皮肤病

甲氨蝶呤早期反应不佳预示中重度银屑病患者长期结局不充分:两项3期临床试验证据

Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.
PubMed 文献 · J Am Acad Dermatol · 2017-10-06

研究基于CHAMPION试验(N=110)构建预测模型,用基线特征和第4周PASI25预测第16周PASI75,并在M10-255试验(N=163)中验证。第4周达到PASI25高度预测甲氨蝶呤第16周反应(OR=8.917),预测反应概率<30%者建议停药,继续组与停药组第16周PASI75率分别为65.8%和21.1%(P<.001)。结论:4周甲氨蝶呤可能足以预测长期反应且安全性风险有限。

要点

  • 第4周达到PASI25可高度预测甲氨蝶呤第16周PASI75反应(OR=8.917)。
  • 预测反应概率<30%的患者建议停用甲氨蝶呤。
  • 继续组与停药组第16周PASI75率分别为65.8%和21.1%(P<.001)。

核心结论

  • 开发并验证了预测规则,可识别不太可能对甲氨蝶呤充分反应的患者。
  • 该规则提示4周甲氨蝶呤可能足以预测长期反应且安全性风险有限。

研究设计与样本

  • 使用CHAMPION试验(NCT00235820,N=110)的患者个体数据构建预测模型,以基线特征和第4周PASI25预测第16周PASI75。
  • 在M10-255试验(NCT00679731,N=163)的独立验证样本中验证第16周PASI75反应。

主要发现

  • 第4周达到PASI25对甲氨蝶呤第16周反应有高度预测性(OR=8.917)。
  • 预测反应概率<30%的患者被建议停用甲氨蝶呤。
  • 建议继续与建议停药患者的第16周PASI75率分别为65.8%和21.1%(P<.001)。

关键数值与推荐

  • 第4周PASI25的OR=8.917。
  • 预测反应概率<30%建议停用甲氨蝶呤。
  • 继续组第16周PASI75率65.8%,停药组21.1%(P<.001)。

临床怎么用

  • 可在甲氨蝶呤治疗4周时评估PASI25,结合预测模型识别可能长期反应不足的患者。
  • 对预测反应概率<30%者,可考虑停用甲氨蝶呤并调整治疗策略。

局限性

  • CHAMPION试验排除了既往接受生物制剂治疗的患者,而M10-255试验无此限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most methotrexate-treated psoriasis patients do not achieve a long-term PASI75 (75% reduction from baseline Psoriasis Area and Severity Index score) response. Indications of nonresponse can be apparent after only 4 weeks of treatment. OBJECTIVE: To develop a prediction rule to identify patients unlikely to respond adequately to methotrexate. METHODS: Patient-level data from CHAMPION (NCT00235820, N = 110) was used to construct a prediction model for week 16 PASI75 by using patient baseline characteristics and week 4 PASI25. A prediction rule was determined on the basis of the sensitivity and specificity and validated in terms of week 16 PASI75 response in an independent validation sample from trial M10-255 (NCT00679731, N = 163). RESULTS: PASI25 achievement at week 4 (odds ratio = 8.917) was highly predictive of response with methotrexate at week 16. Patients with a predicted response probability <30% were recommended to discontinue methotrexate. The rates of week 16 PASI75 response were 65.8% and 21.1% (P < .001) for patients recommended to continue and discontinue methotrexate, respectively. LIMITATIONS: The CHAMPION trial excluded patients previously treated with biologics, and the M10-255 trial had no restrictions. CONCLUSION: A prediction rule was developed and validated to identify patients unlikely to respond adequately to methotrexate. The rule indicates that 4 weeks of methotrexate might be sufficient to predict long-term response with limited safety risk.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Gordon KB, Betts KA, Sundaram M, et al. Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials. J Am Acad Dermatol. 2017. PMID: 28993007. doi:10.1016/j.jaad.2017.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。